PROGRAM

List of Participants .......................................................... 563

Approaches to Immunological Control of Virus-associated Tumors in Man: Introductory Remarks.

Paul H. Levine .......................................................... 565

ACUTE LEUKEMIA

Chairpersons: Dani P. Bolognesi and James F. Holland

The Epidemiology of Avian Lymphoid Leukosis.

L. B. Crittenden ........................................................................... 570

The Epidemiology and Virology of C-type Virus-associated Hematological Cancers and Related Diseases in Wild Mice.

Murray B. Gardner, Brian E. Henderson, John D. Estes, Robert W. Rongey, John Casagrande, Malcolm Pike, and Robert J. Huebner ................................................................. 574

Biology of Feline Leukemia Virus in the Natural Environment.

William D. Hardy, Jr., Paul W. Hess, E. Gregory MacEwen, Alexander J. McClelland, Evelyn E. Zuckerman, Myron Essex, Susan M. Cotter, and Oswald Jarrett .................................................. 582


Clark W. Heath, Jr ................................................................. 589

C-type Virus-associated Antigens and Their Relevance to Human Leukemia Control.

Tadao Aoki and Louis R. Sibal .................................................... 591

Immune Response to Oncornaviruses and Tumor-associated Antigens in the Chicken.

H. Bauer, R. Kurth, L. Rohrschneider, and H. Gelderblom ............ 598

Physiopathology of Human and Virus-induced Murine Leukemias.

Claude Jasmin, Florence Smadja-Joffe, Bernard Klein, and Caroline Kerdiles-LeBousse ......................................................... 603

Autogenous Immunity to Endogenous RNA Tumor Virus: Humoral Immune Response to Virus Envelope Antigens.

M. G. Hanna, Jr., J. N. Ihle, and J. C. Lee ...................................... 608

Cell-mediated Immunity to Leukemia Virus- and Tumor-associated Antigens in Mice.

Ronald B. Herberman, Howard T. Holden, Chou-Chik Ting, David L. Lavrin, and Holger Kirchner ...................................................... 614

An Approach to C-type Virus Immunoprevention of Spontaneously Occurring Tumors in Laboratory Mice.


Treatment of Spontaneous Leukemia in AKR Mice with Chemotherapy, Immunotherapy, or Interferon.

J. George Bekesi, Julia P. Roboz, Eugene Zimmerman, and James F. Holland ............................................................. 631

Immune Response to Leukemia Virus and Tumor-associated Antigens in Cats.

M. Essex, A. Sliski, W. D. Hardy, Jr., and S. M. Cotter .................... 640

Experimental Oncornavirus Vaccines in the Cat.

D. S. Yohn, R. G. Olsen, J. P. Schaller, E. A. Hoover, L. E. Mathes, L. Heding, and G. W. Davis ...................................................... 646


Robert N. Hoover ..................................................................... 652

Potential Leukemia Virus Subunit Vaccines: Discussion.

Dani P. Bolognesi .................................................................... 655

Immunological Control of Human Leukemia: Discussion. 

James F. Holland .................................................................... 657

HODGKIN'S DISEASE AND BURKITT'S LYMPHOMA

Chairpersons: Eva Klein and Paul H. Levine


P. G. Smith and M. C. Pike .......................................................... 660

Evidence for Infectious Component of Hodgkin’s Disease and Related Considerations.

N. J. Vianna ............................................................................. 663

Epstein-Barr Virus-Malaria Interaction Models for Burkitt’s Lymphoma: Implications for Preventive Trials.

R. H. Morrow, N. Gutensohn, and P. G. Smith ................................ 667

Experimental Models for DNA-RNA Viral Interactions: A Brief Review.

Jack W. Frankel ....................................................................... 670

An Animal Model for DNA-RNA Virus interaction Based upon Virological and Histological Findings.

G. D. Hsiung and A. H. McTighe ................................................ 674

Biochemical Approaches to Detection of Epstein-Barr Virus in Human Tumors.

Harald zur Hausen ..................................................................... 678
Natural Mechanisms of Controlling Lymphotropic Herpesvirus Infection (Marek's Disease) in the Chicken.

R. L. Witter ................................................................. 681

Immune Response of Monkeys to Lymphotropic Herpesvirus Antigens.

Gary R. Pearson and Stephen Davis ........................................... 688

Epstein-Barr Virus Behavior in Different Populations and Implications for Control of Epstein-Barr Virus-associated Tumors.

Guy de-Thé ................................................................. 692

Prevention of Marek's Disease: A Review.

H. Graham Purchase ......................................................... 696

Preventive Vaccination against Herpesvirus saimiri-induced Neoplasia.

Dharam V. Ablashi and John M. Easton ................................... 701

Vaccination of Nonhuman Primates with Killed Oncogenic Herpesviruses.

Rainer Laufs and Hans Steinke .............................................. 704

Experimental Infection of Squirrel and Marmoset Monkeys with Attenuated Herpesvirus saimiri.

Lawrence Falk, John Wright, Friedrich Deinhardt, Lauren Wolfe, Priscilla Schaffer, and Matilda Benyesh-Melnick ................................................................. 707

Implications of a Vaccine for the Prevention of Epstein-Barr Virus Infection: Ethical and Logistic Considerations.

M. A. Epstein ........................................................................... 711

Pilot Studies with Human Interferon in Herpesvirus saimiri-induced Lymphoma in Owl Monkeys.

Harvey Rabin, Richard H. Adamson, Russell H. Neubauer, John L. Cicmanec, and William C. Wallen ................................................................. 715

In Vivo and in Vivo Studies of Immunotherapy of Nasopharyngeal Carcinoma with Transfer Factor.

Gerald J. Goldenberg and Lorne J. Brandes ................................ 720

Immunological Control of Human Lymphoma: Discussion.

E. Klein, G. Klein, and P. H. Levine ........................................... 724

BREAST CANCER

Chairpersons: Osias Stutman and Ronald B. Herberman

Murine and Rat Mammary Tumors as Models for the Immunological Study of Human Breast Cancer.

Michael J. Brennan ........................................................................ 728

Natural Immunity in the Oncornavirus-infected Mouse.

Phyllis B. Blair ........................................................................... 734

Correlation of in Vitro and in Vivo Studies on Antigens Relevant to the Control of Murine Breast Cancer.

Osias Stutman ........................................................................... 739

In Vitro Immune Responses to Viral and Tumor Antigens in Murine Breast Cancer.

M. Michael Sigel, Diana M. Lopez, and Gabriel Ortiz-Muniz .................. 748

Microcytotoxicity Assay of Immune Responses to Non-Mammary Tumor Virus-induced, Preneoplastic, and Neoplastic Mammary Lesions in BALB/c Mice.

G. H. Heppner, J. S. Kopp, and D. Medina ......................................... 753

Implications of Humoral Antibody in Mice and Humans to Breast Tumor and Mouse Mammary Tumor Virus-associated Antigens.

J. M. Bowen, L. Dmochowski, M. F. Miller, E. S. Priori, G. Seman, M. L. Dodson, and K. Maruyama ................................................................. 759

Human Antibodies Binding to the Mouse Mammary Tumor Virus: A Nonspecific Reaction?

Kent W. Newgard, Robert D. Cardiff, and Phyllis B. Blair ......................... 765

Biological Considerations of Tumor-specific and Virus-associated Antigens of Human Breast Cancers.

Maurice M. Black, Reinhard E. Zachrau, Bella Shore, and Henry P. Leis, Jr. ................................................................. 769


Wade Parks ........................................................................... 775

Further Immunization Studies with Mammary Tumor Virus.

Jesse Charney, Jane A. Holben, Christine M. Cody, and Dan H. Moore ................................................................. 777

Immunological Control of Breast Cancer: Discussion.

Osias Stutman and Ronald B. Herberman ........................................... 781

CERVICAL CANCER

Chairpersons: Joseph L. Melnick and Alan S. Rabson

Human Cervical Cancer as a Venereal Disease.

Irving I. Kessler .......................................................................... 783

Model Systems for Cervical Cancer.

Nubia Muñoz ........................................................................... 792
Condylomata Acuminata and Human Genital Cancer.
Harald zur Hausen

A Search for Herpes Simplex Virus Type 2 Markers in Cervical Carcinoma.
Robert J. Goldberg and Maneth Gravell

Experimental Evidence for the Oncogenic Potential of Herpes Simplex Virus.
Fred Rapp and Cathy Reed

A Preliminary Report on Investigation of Oncogenic Potential of Herpes Simplex Virus Type 2 in Cebus Monkeys.

Herpesvirus Type 2-related Antigens and Their Relevance to Humoral and Cell-mediated Immunity in Patients with Cervical Cancer.
L. Aurelian and B. C. Strnad

In vivo and In Vitro Measurements of the Relationship of Human Squamous Carcinomas to Herpes Simplex Virus Tumor-associated Antigens.
Ariel C. Hollinshead, Paul B. Chretien, O'Bong Lee, John L. Tarpley, Suzanne E. Kerney, Norman A. Silverman, and John C. Alexander

Serological and Epidemiological Considerations of the Role of Herpes Simplex Virus Type 2 in Cervical Cancer.
William E. Rawls, Christine H. Garfield, Pradeep Seth, and Ervin Adam

Immunology of Herpes Simplex Virus Infection: Relevance to Herpes Simplex Virus Vaccines and Cervical Cancer.
André J. Nahmias, Steven L. Shore, Steve Kohl, Stuart E. Starr, and Robert B. Ashman

Studies on Herpes Simplex Virus and Cancer.
Joseph L. Melnick, Richard J. Courtney, Kenneth L. Powell, Priscilla A. Schaffer, Matilda Benyesh-Melnick, Gordon R. Dreesman, Takashi Anzai, and Ervin Adam

Herpes Simplex Vaccines.
Maurice R. Hilleman

Immunological Control of Cervical Cancer: Discussion.
Joseph L. Melnick

GENERAL CONSIDERATIONS AND SUMMARY

Practical Considerations in the Development of a Human Cancer Vaccine.
S. A. Mayyasi, D. L. Larson, and M. Ahmed

Regulatory Approach toward Vaccines against Cancer: The Benefit/Risk Ratio.
Harry M. Meyer, Jr., and Francis A. Ennis

Immunological Control of Virus-associated Tumors in Man: A Perspective.
Paul H. Levine